Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

• ClinicalTrials.gov Identifier: NCT02757105
• Recruitment Status: Completed
• First Posted: April 29, 2016
• Results First Posted: July 31, 2018
• Last Update Posted: August 28, 2018
• Sponsor: RedHill Biopharma Limited
• Information provided by (Responsible Party): RedHill Biopharma Limited

Study Description

Brief Summary:

This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency and frequency data and symptom data will be collected. Patients will then be randomized 60:40 to RHB-102 12 mg (BEKINDA) or placebo. Patients will continue on treatment for 8 weeks. Each medication will be given once daily.

Condition or disease	Intervention/treatment	Phase
Irritable Bowel Syndrome With Diarrhea	Drug: BEKINDA; Drug: Placebo	Phase 2

Detailed Description:

All patients will undergo baseline evaluation including full history and physical, with particular attention to gastrointestinal symptomatology and findings, a standard set of safety laboratory examinations (CBC and platelet count, biochemical profile, urinalysis, serum thyroid-stimulating hormone (TSH) and free T4, INR), and 12-lead ECG. In addition, the following studies will be performed to exclude other causes of gastrointestinal symptoms:

• Serum testing for C-reactive protein and gluten sensitivity
• Colonoscopy if required per protocol
• Patients with a history of positive tests for ova, parasites or Clostridium difficile must undergo repeat testing, which must be negative, during the screening period. Starting during the baseline observation phase, all patients will keep diaries of symptomatology and stool frequency and consistency. Stool consistency will be assessed according to the Bristol Stool Form scale (Lewis and Heaton, 1997).

Patients will keep diaries of stool frequency and consistency, symptoms, study medication compliance, and use of all medications, including rescue medications, throughout the study.

Serum electrolyte assays (bicarbonate, calcium, chloride, magnesium, potassium, and sodium) will be performed at week 3 on study. Safety laboratory examinations will be performed during and after the treatment period in accordance with the study procedures schedule below.

Patients will be questioned periodically regarding concomitant medication use and the occurrence of adverse events.

Patients must complete at least 12 days of all baseline diary entries within the 14 day screening period to be eligible to participate in the study. Patients completing fewer than 12 days of diary entries may, at the investigator's discretion, repeat the screening period diary. As long as the patent can complete and enter the study within 6 weeks, baseline laboratory studies need not be repeated. If repeating the 2 weeks' baseline diary will result in a period longer than 6 weeks from consent to start of treatment, the medical monitor must be consulted prior to randomization.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 127 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
• Actual Study Start Date: May 19, 2016
• Actual Primary Completion Date: June 16, 2017
• Actual Study Completion Date: July 14, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group A; BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks	Drug: BEKINDA; Other Names: RHB-102 12 mg; Ondansetron Bimodal Release Tablet 12 mg
Placebo Comparator: Group B; Placebo, once daily for 8 weeks	Drug: Placebo

Outcome Measures

Primary Outcome Measures :

1. Summary and Analysis of Overall Stool Consistency Response Rate - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.
2. Summary and Analysis of Overall Stool Consistency Response Rate Males - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.
3. Summary and Analysis of Overall Stool Consistency Response Rate Females - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.
4. Summary and Analysis of Overall Stool Consistency Response Rate: Sensitivity Analysis Without Imputation for Use of Rescue Medication - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.
5. Summary and Analysis of Overall Stool Consistency Response Rate by Baseline CRP > Median - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.
6. Summary and Analysis of Overall Stool Consistency Response Rate by Baseline CRP ≤ Median - mITT Population [ Time Frame: 8 weeks ]
   A weekly stool consistency responder was defined in the FDA guidance on IBS-D as a patient who experienced (during a week) a ≥50% reduction in the number of days with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared with baseline. In addition, to be considered a responder for the week, the patient could not have had an increase in average abdominal pain >10% over baseline during that week. A patient was characterized as an overall stool consistency responder if the patient was a weekly responder for at least 50% of the planned weeks of treatment.

Secondary Outcome Measures :

1. Summary and Analysis of Overall Worst Abdominal Pain Response Rate - mITT Population [ Time Frame: 8 weeks ]
   A weekly pain responder was defined as a patient who experienced a decrease in the weekly average of worst abdominal pain in the past 24 hours score ≥30% compared with baseline and no increase in the number of days per week with Type 6 or 7 stool consistency. An overall pain responder was defined as a patient who was a weekly pain responder for at least 50% of the planned weeks of treatment.
2. Summary and Analysis of Overall Study Response Rate - mITT Population [ Time Frame: 8 weeks ]
   A patient was characterized as an overall weekly responder if the patient met both the stool consistency and pain response definitions for a given week. A patient was characterized as a composite study responder if the patient met the criteria for both weekly stool consistency and pain response for at least 50% of the planned weeks of treatment.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male and female patients age≥18 years (with a minimum of 35% males in the study)

2. Patient meets FDA guidance and Rome III criteria for IBS-D:

   a. Recurrent abdominal pain or discomfort over ≥6 months, with frequency ≥3 days/month in the last 3 months associated with ≥2 of the following: i. Improvement with defecation ii. Onset associated with a change in frequency of stool iii. Onset associated with a change in the form of stool b. Loose or watery stools (Bristol stool form scale 6 or 7) ≥2 days per week

3. Average worst daily pain intensity ≥3.0 for each of the two baseline weeks

4. Major laboratory parameters within the following limits (no worse than grade 1 abnormalities per NCI-CTCAE v4):

   a. Adequate hematologic function, as demonstrated by i. Hemoglobin ≥10 g/dL ii. Absolute neutrophil count (ANC) 1.5-10 x 10^9/L iii. Platelets ≥100 x 10^9/L b. Adequate liver and renal function as demonstrated by i. Aspartate transaminase (AST) and Alanine transaminase (ALT) each ≤ 3.0 x upper limit of normal (ULN) ii. Total bilirubin ≤1.5 x ULN iii. Creatinine ≤1.5 X ULN c. Euthyroid based on thyroid-stimulating hormone (TSH) and free T4 levels

5. Patients on thyroid hormone replacement must be on a stable dose for at least one month prior to study entry.
6. C-reactive protein ≤2 x ULN for lab
7. Patients of childbearing potential and male patients with partners of childbearing potential must utilize effective contraceptive measures Women of childbearing potential are women who have menstruated in the past 12 months, with the exception of women who have undergone surgical sterilization
8. All patients must sign informed consent.

Exclusion Criteria:

1. Evidence of other cause for bowel disease:

   1. Relevant abnormalities seen on colonoscopy if previously performed or if required per this protocol. These include but are not limited to Crohn's disease, ulcerative colitis, diverticulitis, ischemic colitis, microscopic colitis.
   2. History of and/or positive serologic test for celiac disease
   3. Known or suspected lactose intolerance.
2. History of abdominal surgery other than appendectomy or cholecystectomy at any time
3. Any elective major surgery (of any organ) planned for the period of the study, including follow-up
4. History of organic abnormalities of the GI tract including but not limited to intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, adhesions or impaired intestinal circulation (e.g., aortoiliac disease)
5. Current or previous diagnosis of neoplasia (except non-GI neoplasia in complete remission ≥5 years, squamous and basal cell carcinomas). With approval of the medical monitor patients with curatively treated neoplasm in complete remission <5 years may be entered in the study.
6. Patients with a history of positive tests for ova or parasites or Clostridium difficile must be retested during the screening period and tests for the relevant agents must be negative
7. Use of any 5-HT3 antagonist (5hydroxytryptamine receptor antagonists) within 4 weeks of the start of baseline data collection.
8. Use of rifaximin within 4 months of the start of baseline data collection.
9. Use of any other agent specific for IBS (such as alosetron or eluxadoline) or for symptomatic treatment of IBS (such as antispasmotics and antidiarrheals other than loperamide) within 2 weeks of the start of baseline data collection.
10. Uses of any investigational agent for any indication within 4 weeks of the start of baseline data collection.
11. Congestive heart failure, bradyarrhythmia (baseline pulse<55/min), known long QT syndrome

12. Patients who have Corrected QT interval (QTc) prolongation>450 msec noted on screening ECG, or who are taking medication known to cause QT prolongation

    Note: For current list of medications known to cause QT prolongation see:

    https://www.crediblemeds.org/healthcare-providers/drug-list/ There are several risk categories. Use the list showing those drugs known to cause torsade de pointes (TdP)

13. Hypersensitivity or other known intolerance to ondansetron or other 5-HT3 antagonists
14. Patient has taken apomorphine within 24 hours of screening
15. Pregnant or lactating
16. Patients with other major illnesses, either physical or psychiatric, or social situations which may interfere with participation in the study or interpretation of results
17. Patients with severe hepatic impairment, defined as Child-Pugh score ≥10 at baseline

Contacts and Locations

Locations

United States, Alabama

Clinical Research Associates, LLC

Huntsville, Alabama, United States, 35801

E Squared Research, Inc.

Huntsville, Alabama, United States, 35801

United States, Arkansas

Endoscoopy Center of AR

Little Rock, Arkansas, United States, 72212

Arkansas Gastroenterology, P.A.

North Little Rock, Arkansas, United States, 72117

United States, California

Prx Clinical

Garden Grove, California, United States, 92840

Providence Clinical Research

North Hollywood, California, United States, 91606

Shahram Jacobs MD, Inc.

Sherman Oaks, California, United States, 91403

Advanced Rx Clinical Research Group, Inc.

Westminster, California, United States, 92683

United States, Connecticut

Bristol Hospital Dba Connecticut Gastroenterology Institute

Bristol, Connecticut, United States, 06010

United States, Florida

Clinical Research of Homestead

Homestead, Florida, United States, 33030

United States, North Carolina

PMG Research of Winston-Salem

Winston-Salem, North Carolina, United States, 27103

United States, Ohio

Great Lakes Medical Research

Mentor, Ohio, United States, 44060

United States, Tennessee

Clinsearch

Chattanooga, Tennessee, United States, 37421

New Phase Research & Development

Knoxville, Tennessee, United States, 37909

United States, Texas

Aztec Medical Research, LLC

Channelview, Texas, United States, 77530

Gastroenterology Research of San Antonio

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

RedHill Biopharma Limited

  Study Documents (Full-Text)

Documents provided by RedHill Biopharma Limited:

Study Protocol  [PDF] February 16, 2017

Statistical Analysis Plan  [PDF] June 28, 2017

More Information

• Responsible Party: RedHill Biopharma Limited
• ClinicalTrials.gov Identifier: NCT02757105
• Other Study ID Numbers: RHB-102-02
• First Posted: April 29, 2016
• Results First Posted: July 31, 2018
• Last Update Posted: August 28, 2018
• Last Verified: July 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Irritable Bowel Syndrome; Syndrome; Diarrhea; Disease; Pathologic Processes; Signs and Symptoms, Digestive; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Ondansetron; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Antipruritics; Dermatologic Agents; Serotonin Antagonists; Serotonin Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Psychotropic Drugs; Anti-Anxiety Agents